Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis.
- Authors
- Skinner, Marilyn D; Lahmek, Pierre; Pham, HΓ©loΓ―se; Aubin, Henri-Jean
- Year
- 2014
- Journal
- PloS one
- PMID
- 24520330
- DOI
- 10.1371/journal.pone.0087366
- PMCID
- PMC3919718
BACKGROUND: Despite its success with compliant or supervised patients, disulfiram has been a controversial medication in the treatment of alcoholism. Often, study designs did not recognize a pivotal factor in disulfiram research, the importance of an open-label design. Our objectives are: (1) to analyze the efficacy and safety of disulfiram in RCTs in supporting abstinence and (2) to compare blind versus open-label studies, hypothesizing that blinded studies would show no difference between disulfiram and control groups because the threat would be evenly spread across all groups. METHODS AND FINDINGS: We searched PubMed, EMBASE and the Cochrane Central Register for RCTs on disulfiram use with alcoholics in comparison to any alcoholic control group. The primary outcome was defined by the authors of each trial. Additional analyses included: blind vs. open-label, with or without supervision, cocaine study or not, and type of control. Overall, the 22 included studies showed a higher success rate of disulfiram compared to controls Hedges'g =β.58 (95%CI =β.35-.82). When comparing blind and open-label RCTs, only open-label trials showed a significant superiority over controls g =β.70 (95%CI =β.46-.93). RCTs with blind designs showed no efficacy of disulfiram compared to controls. Disulfiram was also more effective than the control condition when compared to naltrexone g =β.77, 95%CI =β.52-1.02, to acamprosate g =β.76, 95%CI =β.04-1.48, and to the no disulfiram groups g =β.43, 95%CI =β.17-.69. LIMITS INCLUDE: (1) a population of 89% male subjects and (2) a high but unavoidable heterogeneity of the studies with a substantial I-square in most subgroups of studies. CONCLUSIONS: Blinded studies were incapable of distinguishing a difference between treatment groups and thus are incompatible with disulfiram research. Based on results with open-label studies, disulfiram is a safe and efficacious treatment compared to other abstinence supportive pharmacological treatments or to no disulfiram in supervised studies for problems of alcohol abuse or dependence.
Flowchart of selection of studies for inclusion in the meta-analysis.
LLM interpretation
This is a PRISMA-style flowchart detailing the study selection process for a meta-analysis. It shows the progression from 316 initial records (313 from systematic searches and 3 from hand searches) to 216 unique studies after removing 100 duplicates. Following the exclusion of 193 studies for specific reasons (e.g., non-efficacy, non-alcohol studies) and one study due to insufficient data, a final total of 22 studies met the criteria for inclusion.
Meta-analysis of Hedges' g effect-size of all RCTs comparing the efficacy of disulfiram and controls.
LLM interpretation
This figure is a forest plot presenting a meta-analysis of Hedges' g effect sizes from multiple randomized controlled trials (RCTs) comparing disulfiram to control groups. The plot lists individual study names with their corresponding effect sizes, 95% confidence intervals, and p-values, with a red diamond at the bottom representing the pooled aggregate effect. Most individual study markers and the overall summary diamond are positioned to the right of the zero line, indicating a general trend toward greater efficacy for disulfiram.
Meta-analysis for blinded versus open-label RCTs.Meta-analysis of Hedges' g effect-size comparing the efficacy of disulfiram and controls in blinded versus open-label RCTs.
LLM interpretation
This is a forest plot presenting a meta-analysis of Hedges' g effect sizes comparing disulfiram to controls, stratified by study design (blinded vs. open-label RCTs). The blinded group shows a pooled effect size near zero with a confidence interval crossing the line of null effect, while the open-label group shows a pooled effect size shifted toward disulfiram with a statistically significant p-value of 0.000. Individual study effect sizes and their 95% confidence intervals are plotted for both subgroups, with red diamonds representing the overall pooled estimates.
Meta-analysis of RCTs with supervision versus no supervision.Meta-analysis of Hedges' g effect-size comparing the efficacy of disulfiram and controls in RCTs with supervision versus no supervision.
LLM interpretation
This is a forest plot presenting a meta-analysis of Hedges' g effect sizes comparing disulfiram versus controls, stratified by supervision status. The "Supervision" group shows a consistent trend toward the right (disulfiram), with a summary diamond indicating a statistically significant positive effect size. In contrast, the "No supervision" group shows more varied results with a summary diamond closer to the zero line, indicating lower efficacy.
Meta-analysis of RCTs that included cocaine versus non cocaine subjects.Meta-analysis of Hedges' g effect-size comparing the efficacy of disulfiram and controls in RCTs that included alcohol dependent cocaine subjects versus those that did not include cocaine subjects.
LLM interpretation
This is a forest plot presenting a meta-analysis of Hedges' g effect sizes comparing disulfiram to controls in RCTs, stratified by the presence of cocaine use. The "Cocaine RCT" group shows a higher pooled effect size (diamond) favoring disulfiram compared to the "Non cocaine RCT" group. Individual study data include Hedges' g, 95% confidence intervals, and p-values, with the x-axis ranging from -4.00 to 4.00.
Subgroup analysis of Hedges' g effect-size comparing the efficacy of disulfiram and controls by control types.
LLM interpretation
This is a forest plot showing a subgroup analysis of Hedges' g effect sizes comparing the efficacy of disulfiram against various control types (Acamprosate, Olanzapine, Naltrexone, no disulfiram, and Topiramate). Most individual study markers and subgroup diamonds are positioned to the right of the zero line, indicating a general trend toward greater efficacy for disulfiram. The x-axis represents the effect size ranging from -4.00 to 4.00, with specific columns providing the Hedges' g value, 95% confidence intervals, and p-values for each study.
Meta-analysis of adverse events rate ratio comparisons in controls and disulfiram treated patients.
LLM interpretation
This is a forest plot representing a meta-analysis of adverse event rate ratios comparing control groups to disulfiram-treated patients across 16 studies. The x-axis shows the rate ratio and 95% confidence intervals (CI), with a vertical line at 1 indicating no difference between groups. The overall pooled effect, represented by the red diamond, is positioned to the right of the line (Rate Ratio: 1.402, p=0.042), indicating a statistically significant increase in adverse events for the disulfiram group.
No entities extracted from this document yet.
No uploaded files.
| Citation | PMID | DOI | Status |
|---|---|---|---|
| AlharbiFFae-G (2013) N (2013) The relative safety of disulfiram. Addictive Disorders & Their Treatment 12(3) 12: 140β147. | β | β | β |
| AntonRF (2001) Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry 62 Suppl 2011β17.11584870 | β | β | β |
| AzrinNH, SissonRW, MeyersR, GodleyM (1982) Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatry 13: 105β112.713040610.1016/0005-7916(82)90050-7 | β | β | β |
| Bardeleben UK, H.; Biedert, E.; Ihde, T.; Ladewig, D. (1999) Randomized open efficacy study of naltrexone vs. acamprosate vs. disulfiram combined with cognitive-behavioral psychotherapy in preventing alcohol relapse. In: Ladewig D, editor. Basic and Clinical Science of Substance Related Disorders. Basel: Karger. pp. 45β48. | β | β | β |
| BeattieMC, LongabaughR (1999) General and alcohol-specific social support following treatment. Addict Behav 24: 593β606.1057429910.1016/s0306-4603(98)00120-8 | β | β | β |
| Brewer C (2001) Disulfiram for alcohol abuse: Why is such an effective drug so under-prescribed? Primary Care in the New NHS Autumn: 227β231. | β | β | β |
| BrewerC (1986) Patterns of compliance and evasion in treatment programmes which include supervised disulfiram. Alcohol Alcohol 21: 385β388.3814254 | β | β | β |
| BrewerC, MeyersR, JohnsonJ (2000) Does disulfiram help to prevent relapse in alcohol abuse? CNS Drugs 14: 329β341. | β | β | β |
| BrewerC, StreelE (2003) Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive βimmersionβ methods of foreign language teaching. Subst Abus 24: 157β173.1291336510.1080/08897070309511545 | β | β | β |
| CarrollC, ZiedonisD, O'MalleyS, McCance-KatzE, GordonL, et al (1993) Pharmacologic interventions for alcohol and cocaine abusing individuals - a pilot study of disulfiram and naltrexone. American Journal on Addictions 2: 77β79. | β | β | β |
| CarrollK, FetnonLR, BaleSA, NichC, FrankforterTL, et al (2004) Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients. Archives of General Psychiatry 61: 264β272.1499311410.1001/archpsyc.61.3.264PMC3675448 | β | β | β |
| CarrollKM, FentonLR, BallSA, NichC, FrankforterTL, et al (2004) Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 61: 264β272.1499311410.1001/archpsyc.61.3.264PMC3675448 | β | β | β |
| CarrollKM, NichC, BallSA, McCanceE, RounsavileBJ (1998) Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 93: 713β727.969227010.1046/j.1360-0443.1998.9357137.x | β | β | β |
| CarrollKM, RounsavilleBJ, BryantKJ (1993) Alcoholism in treatment-seeking cocaine abusers: clinical and prognostic significance. J Stud Alcohol 54: 199β208.845971410.15288/jsa.1993.54.199 | β | β | β |
| ChickJ, GoughK, FalkowskiW, KershawP, HoreB, et al (1992) Disulfiram treatment of alcoholism. Br J Psychiatry 161: 84β89.163833510.1192/bjp.161.1.84 | β | β | β |
| ClosserMH, KostenTR (1992) Alcohol and cocaine abuse. A comparison of epidemiology and clinical characteristics. Recent Dev Alcohol 10: 115β128.1317046 | β | β | β |
| Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences: Lawrence Erlbaum Associates. | β | β | β |
| De SousaA, De SousaA (2004) A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol Alcohol 39: 528β531.1552579010.1093/alcalc/agh104 | β | β | β |
| De SousaA, De SousaA (2005) An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 40: 545β548.1604343310.1093/alcalc/agh187 | β | β | β |
| De SousaA, De SousaA (2008) An open randomized trial comparing disulfiram and naltrexone in adolescents with alcohol dependence. Journal of Substance Use 13: 382β388. | β | β | β |
| De SousaA, JagtapJ (2009) An open label trial of naltrexone versus disulfiram in elderly patients with alcohol dependence. JPPS 6: 85β89. | β | β | β |
| De SousaAA, De SousaJ, KapoorH (2008) An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat 34: 460β463.1762944210.1016/j.jsat.2007.05.012 | β | β | β |
| Diehl A, Ulmer L, Mutschler J, Herre H, Krumm B, et al.. (2010) Why is Disulfiram Superior to Acamprosate in the Routine Clinical Setting? A Retrospective Long-Term Study in 353 Alcohol-Dependent Patients. Alcohol Alcohol.10.1093/alcalc/agq01720348436 | β | β | β |
| DobkinPL, DeCM, ParaherakisA, GillK (2002) The role of functional social support in treatment retention and outcomes among outpatient adult substance abusers. Addiction 97: 347β356.1196411110.1046/j.1360-0443.2002.00083.x | β | β | β |
| FullerR, GordisE (2004) Does disulfiram have a role in alcoholism treatment today? Addiction 99: 21β24.1467805510.1111/j.1360-0443.2004.00597.x | β | β | β |
| FullerRK, BrancheyL, BrightwellDR, DermanRM, EmrickCD, et al (1986) Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 256: 1449β1455.3528541 | β | β | β |
| FullerRK, RothHP (1979) Disulfiram for the treatment of alcoholism. An evaluation in 128 men. Ann Intern Med 90: 901β904.38912110.7326/0003-4819-90-6-901 | β | β | β |
| Gaval-CruzM, WeinshenkerD (2009) mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol Interv 9: 175β187.1972075010.1124/mi.9.4.6PMC2861803 | β | β | β |
| GerreinJR, RosenbergCM, ManoharV (1973) Disulfiram maintenance in outpatient treatment of alcoholism. Arch Gen Psychiatry 28: 798β802.470798910.1001/archpsyc.1973.01750360034004 | β | β | β |
| GossopM, CarrollKM (2006) Disulfiram, cocaine, and alcohol: two outcomes for the price of one? Alcohol Alcohol 41: 119β120.1649272510.1093/alcalc/agl003 | β | β | β |
| GrantBF, HarfordTC (1990) Concurrent and simultaneous use of alcohol with cocaine: results of national survey. Drug Alcohol Depend 25: 97β104.232331510.1016/0376-8716(90)90147-7 | β | β | β |
| GrassiMC, CioceAM, GiudiciFD, AntonilliL, NenciniP (2007) Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: A pilot study. Pharmacological Research 55: 117β121.1717410210.1016/j.phrs.2006.11.005 | β | β | β |
| Higgins J, Green Se (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 The Cochrane Collaboration. | β | β | β |
| Higgins JP, Altman DG (2008) Assessing Risk of Bias in Included Studies. In: Higgins JP, Green Se, editors. Cochrane Handbook for Systematic Reviews of Interventions Chichester, UK: John Wiley & Sons. | β | β | β |
| HughesJC, CookCC (1997) The efficacy of disulfiram: a review of outcome studies. Addiction 92: 381β395.9177060 | β | β | β |
| IberFL, LeeK, LacoursiereR, FullerR (1987) Liver toxicity encountered in the Veterans Administration trial of disulfiram in alcoholics. Alcohol Clin Exp Res 11: 301β304.330749810.1111/j.1530-0277.1987.tb01312.x | β | β | β |
| JohnsonBA (2008) Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75: 34β56.1788092510.1016/j.bcp.2007.08.005PMC2359153 | β | β | β |
| JohnsonBA (2010) Medication treatment of different types of alcoholism. Am J Psychiatry 167: 630β639.2051616310.1176/appi.ajp.2010.08101500PMC2939449 | β | β | β |
| Jorgensen CH, Pedersen B, Tonnesen H (2011) The Efficacy of Disulfiram for the Treatment of Alcohol Use Disorder. Alcohol Clin Exp Res.10.1111/j.1530-0277.2011.01523.x21615426 | β | β | β |
| KhalsaH, ParedesA, AnglinMD (1992) The role of alcohol in cocaine dependence. Recent Dev Alcohol 10: 7β35.131704910.1007/978-1-4899-1648-8_1 | β | β | β |
| LaaksonenE, Koski-JannesA, SalaspuroM, AhtinenH, AlhoH (2008) A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 43: 53β61.1796544410.1093/alcalc/agm136 | β | β | β |
| LingW, WeissDG, CharuvastraVC, O'BrienCP (1983) Use of disulfiram for alcoholics in methadone maintenance programs. A Veterans Administration Cooperative Study. Arch Gen Psychiatry 40: 851β854.634711810.1001/archpsyc.1983.01790070041005 | β | β | β |
| MalcolmR, OliveMF, LechnerW (2008) The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice. Expert Opin Drug Saf 7: 459β472.1861380910.1517/14740338.7.4.459 | β | β | β |
| McCance-KatzEF, PriceLH, McDougleCJ, KostenTR, BlackJE, et al (1993) Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology (Berl) 111: 39β46.787093210.1007/BF02257405 | β | β | β |
| MutschlerJ, BuhlerM, GrosshansM, DiehlA, MannK, et al (2010) Disulfiram, an option for the treatment of pathological gambling? Alcohol Alcohol 45: 214β216.2008347910.1093/alcalc/agp093 | β | β | β |
| MutschlerJ, EiflerS, DiricanG, GrosshansM, KieferF, et al (2013) Functional social support within a medical supervised outpatient treatment program. Am J Drug Alcohol Abuse 39: 44β49.2259466910.3109/00952990.2012.677889 | β | β | β |
| NavaF, PremiS, ManzatoE, LucchiniA (2006) Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptionst. J Psychoactive Drugs 38: 211β217.1716536310.1080/02791072.2006.10399846 | β | β | β |
| NiederhoferH, StaffenW (2003) Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents. Drug Alcohol Rev 22: 295β297.1538522310.1080/0959523031000154436 | β | β | β |
| OlivetoA, PolingJ, MancinoMJ, FeldmanZ, CubellsJF, et al (2011) Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend 113: 184β191.2082894310.1016/j.drugalcdep.2010.07.022PMC3005977 | β | β | β |
| Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, et al.. (2010) Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev: CD007024.10.1002/14651858.CD007024.pub220091613 | β | β | β |
| PetrakisIL, CarrollKM, NichC, GordonLT, McCance-KatzEF, et al (2000) Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95: 219β228.1072385010.1046/j.1360-0443.2000.9522198.x | β | β | β |
| PetrakisIL, PolingJ, LevinsonC, NichC, CarrollK, et al (2005) Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 57: 1128β1137.1586655210.1016/j.biopsych.2005.02.016 | β | β | β |
| PettinatiHM, KampmanKM, LynchKG, XieH, DackisC, et al (2008) A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav 33: 651β667.1807906810.1016/j.addbeh.2007.11.011PMC2374760 | β | β | β |
| RegierDA, FarmerME, RaeDS, LockeBZ, KeithSJ, et al (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264: 2511β2518.2232018 | β | β | β |
| SchuckitMA (1996) Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psychol 64: 669β676.880335610.1037//0022-006x.64.4.669 | β | β | β |
| Skinner M, Coudert M, Berlin I, Passeri E, Michel L, et al.. (2010) Effect of the threat of a disulfiram-ethanol reaction on cue reactivity in alcoholics Drug Alcohol Depend.10.1016/j.drugalcdep.2010.06.01120708858 | β | β | β |
| StockwellT, HodgsonR, EdwardsG, TaylorC, RankinH (1979) The development of a questionnaire to measure severity of alcohol dependence. Br J Addict Alcohol Other Drugs 74: 79β87.28383110.1111/j.1360-0443.1979.tb02415.x | β | β | β |
| SuhJJ, PettinatiHM, KampmanKM, O'BrienCP (2006) The status of disulfiram: a half of a century later. J Clin Psychopharmacol 26: 290β302.1670289410.1097/01.jcp.0000222512.25649.08 | β | β | β |
| SwiftRM (1999) Drug therapy for alcohol dependence. N Engl J Med 340: 1482β1490.1032038810.1056/NEJM199905133401907 | β | β | β |
| TΓΈnnesenH, RosenbergJ, NielsenHJ, RasmussenV, HaugeC, et al (1999) Effect of preoperative abstinence on poor postoperative outcome in alcohol misusers: randomised controlled trial. BMJ 318: 1311β1316.1032381410.1136/bmj.318.7194.1311PMC27867 | β | β | β |
| UlrichsenJ, NielsenMK, UlrichsenM (2010) Disulfiram in severe alcoholismβan open controlled study. Nord J Psychiatry 64: 356β362.2029794510.3109/08039481003686180 | β | β | β |
| WeinshenkerD (2010) Cocaine sobers up. Nat Med 16: 969β970.2082387810.1038/nm0910-969 | β | β | β |
| WeissRD, MirinSM, GriffinML, MichaelJL (1988) Psychopathology in cocaine abusers. Changing trends. J Nerv Ment Dis 176: 719β725.319910710.1097/00005053-198812000-00004 | β | β | β |
| WilsonA, BlanchardR, DavidsonW, McRaeL, MainiK (1984) Disulfiram implantation: a dose response trial. J Clin Psychiatry 45: 242β247.6202678 | β | β | β |
| WrightC, MooreRD (1990) Disulfiram treatment of alcoholism. Am J Med 88: 647β655.218931010.1016/0002-9343(90)90534-k | β | β | β |
| YaoL, FanP, ArolfoM, JiangZ, OliveMF, et al (2010) Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis. Nat Med 16: 1024β1028.2072986510.1038/nm.2200PMC3191463 | β | β | β |
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Alcohol reverses the effects of KCNJ6 (GIRK2) noncoding variants on excitability of human glutamatergic neurons. | 2023 | 36207584 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Complementary services improve recovery outcomes among college students with alcohol or other drug related use disorders. | Qeadan F et al. | β | 2026 | β |
| Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology. | Sinclair JM et al. | β | 2026 | β |
| Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies. | Costa GPA et al. | β | 2026 | β |
| Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications. | Gougol A et al. | β | 2026 | β |
| Stigma and knowledge about medications for alcohol use disorder among treatment-seeking adults. | Hilton BT et al. | β | 2026 | β |
| Artemis and its role in cancer. | Parsyan A et al. | β | 2025 | β |
| A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder. | Srivastava AB et al. | β | 2025 | β |
| Clinician Prescribing Practices Involving Medications for Alcohol Use Disorder. | Kennedy-Hendricks A et al. | β | 2025 | β |
| Combined pharmacological and psychosocial interventions for alcohol use disorder. | Minozzi S et al. | β | 2025 | β |
| Effectiveness of Disulfiram as Adjunct to Addiction-Focused Treatment for Persons With Severe Alcohol Use Disorder. | Schallenberg M et al. | β | 2025 | β |
| Emergency department-initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasibility study. | Cowan E et al. | β | 2025 | β |
| Identification and Treatment of Alcohol Use Disorder. | Haber PS | β | 2025 | β |
| Impact of Covid-19 pandemic on trajectories of patients with severe alcohol use disorder treated with disulfiram. | Pilhatsch M et al. | β | 2025 | β |
| Impact of the aldehyde dehydrogenase 2 (ALDH2) gene testing on alcohol drinking behaviors among the Chinese Han population: study protocol of a single-center, open-label, randomized, controlled clinical trial. | Lu D et al. | β | 2025 | β |
| Modern pharmacotherapy guidance for treating alcohol use disorders. | Soyka M et al. | β | 2025 | β |
| Naltrexone Alters Neurochemical and Behavioral Parameters in a Zebrafish Model of Repeated Alcohol Exposure. | Bernardo HT et al. | β | 2025 | β |
| [Patient and quality characteristics in the treatment with disulfiram (Antabus) in the German "Network for Alcohol Aversive Pharmacotherapy"]. | Zimmermann US et al. | β | 2025 | β |
| Pharmacological Treatments in Alcohol Use Disorder and Risk of Alcohol-Related Hospitalizations: A Register Study. | Bach P et al. | β | 2025 | β |
| Potential Therapeutic Role of GLP-1 Receptor Agonists in the Management of Opioid Use Disorders: A Literature Review. | Bronson S et al. | β | 2025 | β |
| Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial. | O'Malley SS et al. | β | 2025 | β |
| Role of Metabolism onΒ Alcohol Preference, Addiction, and Treatment. | Quintanilla ME et al. | β | 2025 | β |
| Surreptitious Administration of Disulfiram Along with Its Implantation Leading to Disulfiram-associated Encephalopathy. | Kalia A et al. | β | 2025 | β |
| The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis. | Sinha B et al. | β | 2025 | β |
| The hepatic and developmental toxicity of chronic morphine and disulfiram co-treatment for pain relief - a comprehensive in vitro and in vivo assessment. | Zelazewska Z et al. | β | 2025 | β |
| Therapy of alcohol use disorder in liver transplant recipients. | Weinrieb R et al. | β | 2025 | β |
| Advances in research on medications for the treatment of alcohol use disorders: A review. | Chen Y et al. | β | 2024 | β |
| Alcohol Abstinence, Adherence, and Attitudes toward Disulfiram Treatment for Alcohol Dependence among Patients Attending a Tertiary Care Setting in North India. | Joseph J et al. | β | 2024 | β |
| Alcohol Use Disorder Treatment: Problems and Solutions. | Koob GF | β | 2024 | β |
| A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder. | Celik M et al. | β | 2024 | β |
| AUD in perspective. | de Bejczy A et al. | β | 2024 | β |
| Current treatments of alcohol use disorder. | Dionisi T et al. | β | 2024 | β |
| Disulfiram Should Remain Second-line Treatment for Most Patients With Alcohol Use Disorder. | Axelrath S | β | 2024 | β |
| Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder. | KΓΆhne S et al. | β | 2024 | β |
| EndpointsΒ for Pharmacotherapy Trials for AlcoholΒ Use Disorder. | Belnap MA et al. | β | 2024 | β |
| Evidence of subgroup differences in meta-analyses evaluating medications for alcohol use disorder: An umbrella review. | Wallach JD et al. | β | 2024 | β |
| IL17RB genetic variants are associated with acamprosate treatment response in patients with alcohol use disorder: A proteomics-informed genomics study. | Ho MF et al. | β | 2024 | β |
| Is internet-based cognitive behavioral therapy for alcohol use disorder equally effective for men and women? Implications of a secondary analysis of a clinical trial. | Schettini G et al. | β | 2024 | β |
| Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes. | Johnson B et al. | β | 2024 | β |
| Management of alcohol-associated liver disease and alcohol use disorder in liver transplant candidates and recipients: Challenges and opportunities. | Sharma P et al. | β | 2024 | β |
| Medicinal plants used by traditional medicine practitioners in treatment of alcohol-related disorders in Bushenyi District, southwestern Uganda. | Maling S et al. | β | 2024 | β |
| Mesenchymal stem cells as a promising therapy for alcohol use disorder. | Gallardo J et al. | β | 2024 | β |
| Molecular mechanisms involved in alcohol craving, IRF3, and endoplasmic reticulum stress: a multi-omics study. | Ho MF et al. | β | 2024 | β |
| Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY<sub>3</sub><sub>-</sub><sub>36</sub> in the suppression of food, drug-seeking, and anxiogenesis. | Dumiaty Y et al. | β | 2024 | β |
| Pharmacological activators of ALDH2: A new strategy for the treatment of alcohol use disorders. | Adasme-Reyes S et al. | β | 2024 | β |
| Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review. | Rosenstand NJ et al. | β | 2024 | β |
| Repurposing drugs for treatment of alcohol use disorder. | Aubin HJ | β | 2024 | β |
| Sobering Perspectives on the Treatment of Alcohol Use Disorder. | Yaseen W et al. | β | 2024 | β |
| Supervised Disulfiram Should Be Considered First-line Treatment for Alcohol Use Disorder. | Holt SR | β | 2024 | β |
| The dual orexin receptor antagonist suvorexant in alcohol use disorder and comorbid insomnia: A case report. | Campbell EJ et al. | β | 2024 | β |
| The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists. | Imperio CG et al. | β | 2024 | β |
| The Roles of Endogenous D2R Dopamine and ΞΌ-opioid Receptors of the Brain in Alcohol use Disorder. | Khikhmetova K et al. | β | 2024 | β |
| Alcohol-Associated Liver Disease: Evolving Concepts and Treatments. | Prince DS et al. | β | 2023 | β |
| Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder. | Arab JP et al. | β | 2023 | β |
| Alcohol reverses the effects of KCNJ6 (GIRK2) noncoding variants on excitability of human glutamatergic neurons. | Popova D et al. | β | 2023 | β |
| Baclofen for alcohol use disorder. | Agabio R et al. | β | 2023 | β |
| Factors Associated with Relapses in Alcohol and Substance Use Disorder. | YazΔ±cΔ± AB et al. | β | 2023 | β |
| Ketamine Treatment for Alcohol Use Disorder: A Systematic Review. | Kelson M et al. | β | 2023 | β |
| Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective. | StokΕosa I et al. | β | 2023 | β |
| Medications for treating alcohol use disorder: A narrative review. | Kranzler HR et al. | β | 2023 | β |
| Precision medicine in alcohol use disorder: Mapping etiologic and maintenance mechanisms to mechanisms of behavior change to improve patient outcomes. | Boness CL et al. | β | 2023 | β |
| Prescribing Medications for Alcohol Use Disorder: A Qualitative Study of Primary Care Physician Decision Making. | Bhardwaj A et al. | β | 2023 | β |
| Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries. | Greene MC et al. | β | 2023 | β |
| Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line. | Lafi Z et al. | β | 2023 | β |
| The management of alcohol use disorder in the emergency department, is it time for version 2.0? | Furlong K et al. | β | 2023 | β |
| Therapeutic Pipeline in Alcohol-Associated Liver Disease. | Thakral N et al. | β | 2023 | β |
| Therapeutic targets in alcohol-associated liver disease: progress and challenges. | Adekunle AD et al. | β | 2023 | β |
| The role of nicotinic receptors in alcohol consumption. | Kamens HM et al. | β | 2023 | β |
| Using naltrexone to validate a human laboratory test system to screen new medications for alcoholism (TESMA)- a randomized clinical trial. | Spreer M et al. | β | 2023 | β |
| Which interventions for alcohol use should be included in a universal healthcare benefit package? An umbrella review of targeted interventions to address harmful drinking and dependence. | Botwright S et al. | β | 2023 | β |
| Alcohol Use. | Donroe JH et al. | β | 2022 | β |
| Alcohol Use Disorder: Neurobiology and Therapeutics. | Yang W et al. | β | 2022 | β |
| Brain Correlates of the Alcohol Use Disorder Pharmacotherapy Response: A Systematic Review of Neuroimaging Studies. | Florence L et al. | β | 2022 | β |
| Clinical management of the alcohol withdrawal syndrome. | Day E et al. | β | 2022 | β |
| Cytotoxic effect of disulfiram/copper on human cervical cancer cell lines and LGR5-positive cancer stem-like cells. | Cao HZ et al. | β | 2022 | β |
| Disulfiram-Induced Urticaria Involving Exclusively the Hands and Feet. | GarcΓa-Souto F | β | 2022 | β |
| Disulfiram Produces Potent Anxiolytic-Like Effects Without Benzodiazepine Anxiolytics-Related Adverse Effects in Mice. | Saitoh A et al. | β | 2022 | β |
| Fabrication, characterization and in vitro evaluation of disulfiram-loaded cellulose acetate/poly(ethylene oxide) nanofiber scaffold for breast and colon cancer cell lines treatment. | El Fawal G et al. | β | 2022 | β |
| Hazardous drinking and alcohol use disorders. | MacKillop J et al. | β | 2022 | β |
| Interactions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review. | D'Alessandro C et al. | β | 2022 | β |
| Looking Back, Looking Forward: Current Medications and Innovative Potential Medications to Treat Alcohol Use Disorder. | Mason BJ | β | 2022 | β |
| Neurobiological mechanisms of control in alcohol use disorder - Moving towards mechanism-based non-invasive brain stimulation treatments. | Ghin F et al. | β | 2022 | β |
| Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. | Burnette EM et al. | β | 2022 | β |
| Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective? | Antonelli M et al. | β | 2022 | β |
| Pharmacological interventions for alcohol misuse in correctional settings: A systematic review. | Slavin-Stewart C et al. | β | 2022 | β |
| Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis. | Bahji A et al. | β | 2022 | β |
| Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder. | Lohoff FW | β | 2022 | β |
| Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives. | Liu SY et al. | β | 2021 | β |
| Alcohol Use Disorder: The Role of Medication in Recovery. | Mason BJ et al. | β | 2021 | β |
| Approaching Alcohol Use Disorder After Liver Transplantation for Acute Alcoholic Hepatitis. | Ting PS et al. | β | 2021 | β |
| Carnitine in Alcohol Use Disorders: A Scoping Review. | Bota AB et al. | β | 2021 | β |
| [CME: Early Recognition and Prevention of a Disulfiram-Ethanol Reaction]. | HΓΌsser L et al. | β | 2021 | β |
| Comparison of Treatments for Cocaine Use Disorder Among Adults: A Systematic Review and Meta-analysis. | Bentzley BS et al. | β | 2021 | β |
| Disulfiram Abrogates Morphine Tolerance-A Possible Role of Β΅-Opioid Receptor-Related G-Protein Activation in the Striatum. | de Corde-Skurska A et al. | β | 2021 | β |
| Drug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent. | Shirley DA et al. | β | 2021 | β |
| Evaluation and Management of Alcohol use Disorder among Older Adults. | Joshi P et al. | β | 2021 | β |
| Is there a case for inclusion of medicines used to manage alcohol use disorder in the World Health Organization Model List of Essential Medicines? | Balhara YPS et al. | β | 2021 | β |
| New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. | Morley KC et al. | β | 2021 | β |
| New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. | Haber PS et al. | β | 2021 | β |
| Outcomes of deep brain stimulation surgery for substance use disorder: a systematic review. | Hassan O et al. | β | 2021 | β |
| Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider? | Kelty E et al. | β | 2021 | β |
| [Pharmacotherapy of alcohol withdrawal: update and new developments]. | Soyka M et al. | β | 2021 | β |
| Pharmacotherapy of substance use disorders in the neuroscience-based nomenclature (NbN). | Carton L et al. | β | 2021 | β |
| Structural and mechanistic insights into the Artemis endonuclease and strategies for its inhibition. | Yosaatmadja Y et al. | β | 2021 | β |
| The effects of pharmacological interventions on smoking cessation in people with alcohol dependence: A systematic review and meta-analysis of nine randomized controlled trials. | Guo K et al. | β | 2021 | β |
| Translational balancing questioned: Unaltered glycosylation during disulfiram treatment in mannosyl-oligosaccharide alpha-1,2-mannnosidase-congenital disorders of glycosylation (MAN1B1-CDG). | Kemme L et al. | β | 2021 | β |
| Veteran adherence to oral versus injectable AUD medication treatment. | Stewart H et al. | β | 2021 | β |
| A sleeping giant: Suvorexant for the treatment of alcohol use disorder? | Campbell EJ et al. | β | 2020 | β |
| Behavioral and neural processes in counterconditioning: Past and future directions. | Keller NE et al. | β | 2020 | β |
| Copper Ionophores as Novel Antiobesity Therapeutics. | Meggyesy PM et al. | β | 2020 | β |
| Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows. | Addolorato G et al. | β | 2020 | β |
| Disulfiram-Induced Baboon Syndrome. | Radaschin DS et al. | β | 2020 | β |
| Drug Repurposing in Medulloblastoma: Challenges and Recommendations. | Hammoud H et al. | β | 2020 | β |
| Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls. | Fairbanks J et al. | β | 2020 | β |
| Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis. | Rogal S et al. | β | 2020 | β |
| On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications. | Nieto SJ et al. | β | 2020 | β |
| Outpatient management of alcohol-related liver disease. | Simonetto DA et al. | β | 2020 | β |
| Pharmacotherapies and personalized medicine for alcohol use disorder: a review. | Lohoff FW | β | 2020 | β |
| Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. | Oldfield BJ et al. | β | 2020 | β |
| Recognition of a disulfiram ethanol reaction in the emergency department is not always straightforward. | Segher K et al. | β | 2020 | β |
| Reply to Brewer: Liver-targeted ALDH2 inhibition may reduce alcohol-seeking behaviors with limited side effects. | Guillot A et al. | β | 2020 | β |
| Treating Alcohol Use Disorder in Chronic Liver Disease. | Yoo ER et al. | β | 2020 | β |
| Treatment interventions to maintain abstinence from alcohol in primary care: systematic review and network meta-analysis. | Cheng HY et al. | β | 2020 | β |
| Advances in the science and treatment of alcohol use disorder. | Witkiewitz K et al. | β | 2019 | β |
| Aldehyde dehydrogenase-2 as a therapeutic target. | Kimura M et al. | β | 2019 | β |
| An integrative bioinformatics pipeline to demonstrate the alteration of the interaction between the ALDH2*2 allele with NAD<sup>+</sup> and Disulfiram. | J CP et al. | β | 2019 | β |
| Applications of <i>Pueraria lobata</i> in treating diabetics and reducing alcohol drinking. | Liu J et al. | β | 2019 | β |
| Characteristics of Patients that Substitute Medical Cannabis for Alcohol | Hayat A et al. | β | 2019 | β |
| Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review. | Butler K et al. | β | 2019 | β |
| Its complicated: The relationship between alcohol and microglia in the search for novel pharmacotherapeutic targets for alcohol use disorders. | Melbourne JK et al. | β | 2019 | β |
| Outcome Assessment in Trials of Pharmacological Treatments for Alcohol Use Disorders: Fair and Strict Testing. | RΓΆsner S et al. | β | 2019 | β |
| Pharmacogenetics of alcohol addiction: current perspectives. | Zastrozhin MS et al. | β | 2019 | β |
| Prevention, screening, and treatment for heavy drinking and alcohol use disorder. | Knox J et al. | β | 2019 | β |
| Rare Anaphylactic Reaction to Acamprosate in a Young Alcoholic. | Patnaik A et al. | β | 2019 | β |
| Receipt of pharmacotherapy for alcohol use disorder by justice-involved women in the Veterans Health Administration. | Taylor E et al. | β | 2019 | β |
| Selecting an appropriate alcohol pharmacotherapy: review of recent findings. | CastrΓ©n S et al. | β | 2019 | β |
| State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. | Ray LA et al. | β | 2019 | β |
| Targeting liver aldehyde dehydrogenase-2 prevents heavy but not moderate alcohol drinking. | Guillot A et al. | β | 2019 | β |
| Trends in first-time treatment admissions for older adults with alcohol use disorder: Availability of medical and specialty clinical services in hospital, residential, and outpatient facilities. | Huhn AS et al. | β | 2019 | β |
| WFSBP <sup>*</sup> and IAWMH <sup>**</sup> Guidelines for the treatment of alcohol use disorders in pregnant women. | Thibaut F et al. | β | 2019 | β |
| Acceptability of pharmacotherapy for hazardous alcohol use among men who have sex with men: Findings from a qualitative study. | Hsiang E et al. | β | 2018 | β |
| Advancing Pharmacotherapy Development from Preclinical Animal Studies. | Egli M | β | 2018 | β |
| An Overview of Pharmacotherapy Options for Alcohol Use Disorder. | Carpenter JE et al. | β | 2018 | β |
| Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. | Rose AK et al. | β | 2018 | β |
| Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. | Kranzler HR et al. | β | 2018 | β |
| Drug Repurposing of Metabolic Agents in Malignant Glioma. | Seliger C et al. | β | 2018 | β |
| Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. | Viudez-MartΓnez A et al. | β | 2018 | β |
| Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. | van den Brink W et al. | β | 2018 | β |
| Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. | Jones JL et al. | β | 2018 | β |
| Gabapentin for the treatment of alcohol use disorder. | Mason BJ et al. | β | 2018 | β |
| Limited modulation of the abuse-related behavioral effects of d-methamphetamine by disulfiram. | de Moura FB et al. | β | 2018 | β |
| Medications for Alcohol Use Disorder and Predicting Severe Withdrawal. | Saitz R | β | 2018 | β |
| Medications for alcohol use disorders: An overview. | Akbar M et al. | β | 2018 | β |
| New steps for treating alcohol use disorder. | Campbell EJ et al. | β | 2018 | β |
| Pharmacotherapy for Alcohol Use Disorder. | Holt SR et al. | β | 2018 | β |
| Pharmacotherapy for relapse prevention of alcohol use disorder in the Indian setting: A systematic review. | Bharadwaj B et al. | β | 2018 | β |
| Receipt of Pharmacotherapy for Alcohol Use Disorder by Male Justice-Involved U.S. Veterans Health Administration Patients. | Finlay AK et al. | β | 2018 | β |
| Fenofibrate Administration Reduces Alcohol and Saccharin Intake in Rats: Possible Effects at Peripheral and Central Levels. | Rivera-Meza M et al. | β | 2017 | β |
| Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. | Soyka M et al. | β | 2017 | β |
| Pattern of prescription, dispensation and administration of disulfiram among patients with alcohol use disorder attending a general hospital psychiatry unit in rural India. | Mangot AG et al. | β | 2017 | β |
| [Pharmacological prophylactic treatment for relapse of alcohol dependence : Results of current meta-analyses]. | Mutschler J et al. | β | 2017 | β |
| Pharmacotherapy of alcoholism - an update on approved and off-label medications. | Soyka M et al. | β | 2017 | β |
| Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. | Goh ET et al. | β | 2017 | β |
| Supervised Disulfiram's Superior Effectiveness in Alcoholism Treatment: Ethical, Methodological, and Psychological Aspects. | Brewer C et al. | β | 2017 | β |
| Alcohol use disorders. | Connor JP et al. | β | 2016 | β |
| Alcohol use in opioid agonist treatment. | Nolan S et al. | β | 2016 | β |
| A Preliminary Study of DBH (Encoding Dopamine Beta-Hydroxylase) Genetic Variation and Neural Correlates of Emotional and Motivational Processing in Individuals With and Without Pathological Gambling. | Yang BZ et al. | β | 2016 | β |
| Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users? | Kleczkowska P et al. | β | 2016 | β |
| Coadministration of disulfiram and lorazepam in the treatment of alcohol dependence and co-occurring anxiety disorder: an open-label pilot study. | Bogenschutz MP et al. | β | 2016 | β |
| Doctors' views of disulfiram and their response to relapse in alcohol-dependent patients, Free State, 2009. | Van Zyl PM | β | 2016 | β |
| Human pharmacology for addiction medicine: From evidence to clinical recommendations. | Quednow BB et al. | β | 2016 | β |
| Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies. | Rolland B et al. | β | 2016 | β |
| Specifying and Pilot Testing Quality Measures for the American Society of Addiction Medicine's Standards of Care. | Harris AH et al. | β | 2016 | β |
| [The practical use of placebo effect in psychotherapeutic treatment of patients with substance use disorders: therapeutic and ethic consequences]. | Tuchina OD et al. | β | 2016 | β |
| The Zebrafish, a Novel Model Organism for Screening Compounds Affecting Acute and Chronic Ethanol-Induced Effects. | Tran S et al. | β | 2016 | β |
| Treatment-Emergent Psychosis With Disulfiram in a Patient With Late-Onset Alcohol Use Disorder and No Contributory Factors. | Thamizh JS et al. | β | 2016 | β |
| Treatment of alcohol use disorders in patients with alcoholic liver disease. | Addolorato G et al. | β | 2016 | β |
| Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. | Soyka M et al. | β | 2016 | β |
| Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions. | Peniche AG et al. | β | 2015 | β |
| Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. | Rubinsky AD et al. | β | 2015 | β |
| Disulfiram for binge eating disorder: an open trail. | Farci AM et al. | β | 2015 | β |
| Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. | Helton SG et al. | β | 2015 | β |
| The "first hit" toward alcohol reinforcement: role of ethanol metabolites. | Israel Y et al. | β | 2015 | β |
| [Use in France of Baclofen for Alcohol Dependence from 2007 to 2013: Cohort Study Based on the Databases SNIIRAM and PMSI]. | Chaignot C et al. | β | 2015 | β |
| Addiction disorders. | Merrill JO et al. | β | 2014 | β |